Search results
Showing 781 to 795 of 1328 results for nice quality standards or clinical guidelines
Transcutaneous electrical neuromuscular stimulation for urinary incontinence (HTG636)
Evidence-based recommendations on transcutaneous electrical neuromuscular stimulation for urinary incontinence in adults. This involves stimulating nerves and muscles in the pelvic floor to strengthen the muscles and reduce urine leaks.
View recommendations for HTG636Show all sections
Evidence-based recommendations on apremilast (Otezla) for treating active psoriatic arthritis.
Our centralised approach to prioritising guidance topics ensures that we produce guidance that is relevant, timely, accessible, and has demonstrable impact.
Support for delivering quality, safety and efficiency in the optimisation of medicines.
Cardiac contractility modulation device implantation for heart failure (HTG520)
Evidence-based recommendations on cardiac contractility modulation device implantation for heart failure in adults. This involves placing a device under the skin of the chest, which delivers electrical pulses to make the heart contract more strongly.
View recommendations for HTG520Show all sections
PleuraFlow Active Clearance Technology for maintaining chest tube patency (MIB125)
NICE has developed a medtech innovation briefing (MIB) on PleuraFlow Active Clearance Technology for maintaining chest tube patency .
trublood-prostate for triaging and diagnosing people with prostate cancer symptoms (MIB268)
NICE has developed a medtech innovation briefing (MIB) on trublood-prostate for triaging and diagnosing people with prostate cancer symptoms .
Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer (HTG642)
Evidence-based recommendations on Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer.
NICE has developed a medtech innovation briefing (MIB) on SYNE-COV for predicting COVID-19 outcomes .
Recommendation ID NG152/1 Question What is the clinical effectiveness of topical treatments (antibiotics and antiseptics) compared with
Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma (TA837)
Evidence-based recommendations on pembrolizumab (Keytruda) for the adjuvant treatment of resected stage 2B and 2C melanoma in people 12 years and over.
How to use NICE guidance to reduce health inequalities in people experiencing cardiovascular disease (CVD).
Idelalisib for treating refractory follicular lymphoma (TA604)
Evidence-based recommendations on idelalisib (Zydelig) for follicular lymphoma that has not responded to 2 prior lines of treatment in adults.
NICE has developed a medtech innovation briefing (MIB) on Biopatch for venous or arterial catheter sites .
iTind for lower urinary tract symptoms caused by benign prostatic hyperplasia (MIB306)
NICE has developed a medtech innovation briefing (MIB) on iTind for lower urinary tract symptoms caused by benign prostatic hyperplasia .